565 PROBING THE METHYLATION STATUS OF DIFFERENT TUMOR SUPPRESSOR GENES FROM BLADDER CANCER PATIENTS

Abstract

You have accessJournal of UrologyBladder Cancer: Basic Research I1 Apr 2012565 PROBING THE METHYLATION STATUS OF DIFFERENT TUMOR SUPPRESSOR GENES FROM BLADDER CANCER PATIENTS Shumaila Bilgrami, shahid pervez, Sohail Qureshi, and Farhat Abbas Shumaila BilgramiShumaila Bilgrami Karachi, Pakistan More articles by this author , shahid pervezshahid pervez Karachi, Pakistan More articles by this author , Sohail QureshiSohail Qureshi Lahore, Pakistan More articles by this author , and Farhat AbbasFarhat Abbas Karachi, Pakistan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.640AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Promoter methylation induced silencing of tumor suppressor genes has been implicated for various genes in bladder cancer. We analyzed the promoter methylation in a panel of tumor suppressor genes involved in apoptosis, DNA repair, cell cycle control and progression in non-invasive and invasive bladder cancer. METHODS Promoter hypermethylation was investigated in the gene promoters of RASSF1a(Ras association domain family member 1), APC (Adenomatous Polyposis Coli), MGMT ( O-6-methylguanine-DNA methyltransferase), p16 and p15 in 43 non-invasive and low grade, 33 invasive and high grade bladder cancer and 10 cases with normal bladder mucosa/benign urologic disease using real-time methylation-specific PCR with SYBR green. In addition to the 86 tissue samples, DNA methylation analyses were also carried out in 16 plasma samples from patients with invasive high grade bladder cancer. RESULTS Promoter hypermethylation was frequently observed in RASSF1a, APC and MGMT genes (p-value<0.001) and was prominent in the invasive high grade bladder cancer tissues as compared to the non-invasive low grade group (p<0.001) and normal bladder mucosa (p-values 0.040, 0.000 and 0.003 for RASSF1a, APC and MGMT, respectively). When the data from16 plasma samples were compared to the corresponding tissue samples, only APC (p-value 0.006) and p16 (p-value 0.011) showed significance in paired-T test. CONCLUSIONS Our results suggest that promoter methylation analysis can serve as a valuable tool for monitoring progression of bladder cancers and assessing their spread. Although the data on plasma samples is preliminary, it has encouraged us to interrogate the DNA methylation status of an expanded panel comprised of oncogenes and tumor-suppressor genes in a larger number of samples. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e231 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Shumaila Bilgrami Karachi, Pakistan More articles by this author shahid pervez Karachi, Pakistan More articles by this author Sohail Qureshi Lahore, Pakistan More articles by this author Farhat Abbas Karachi, Pakistan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...